Targeted Therapeutics Market: Introduction
According to the report, the global targeted therapeutics market was valued over US$ 67.8 Bn in 2020 and is projected to expand at a moderate CAGR during the forecast period. Targeted therapies are drugs or other substances that block the growth of unwanted cells and pathogens by interfering with specific molecules ("molecular targets") involved in the growth, progression, and spread of disease. Targeted therapies are sometimes called molecularly targeted drugs, molecularly targeted therapies, precision medicines, etc. The emerging field of target therapeutics offers varied potential treatments. Targeted therapies offer the possibility of finding a cure for diseases with significant unmet needs, including orphan diseases and diseases having a high burden globally. Targeted therapy is widely used in the treatment of different forms of cancer such as renal, breast, lung, colorectal, and leukemia, and other diseases such as multiple sclerosis and wet age-related macular degeneration. The global targeted therapeutics market is driven by rise in prevalence of cancer across the globe, increase in global geriatric population, and surge in product approvals.
North America dominated the global targeted therapeutics market in 2020, followed by Europe, and the trend is anticipated to continue during the forecast period. North Americas dominance can be ascribed to high prevalence and increase in incidence rates of cancer, well-established healthcare industry, and rise in adoption of targeted therapeutics monoclonal antibodies in the region.
Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=51390
Increase in Incidence of Cancer to Drive Global Market
The increase in incidence of cancers such as breast, lung, and leukemia has fueled the demand for targeted therapeutics. Cancer is a leading cause of death across the globe. It is more prevalent in developed and emerging markets. According to the International Agency for Research on Cancer, one in five persons develops cancer during his or her lifetime, and one in eight men, and one in 11 women succumbs to the disease. Tobacco smoking, pollution, changing lifestyle, and transmission of carcinogens and carcinogenic infections such as HPV, H. Pylori, and HCV have increased the incidence rate of cancer across the globe.
According to the International Agency for Research on Cancer (IARC), an estimated 19.3 million new cancer cases were recorded in 2020 and nearly 10 million individuals died from cancer-related causes. The global burden is expected to increase to 27.5 million new cancer cases and 16.3 million cancer deaths by 2040, primarily due to increase and aging of the population. Targeted therapy has proven to offer promising therapeutic outcomes across a broad range of cancers and is increasingly used in healthcare facilities. Hence, high prevalence and increase in incidence rate of cancer across the globe is a major factor projected to boost the growth of the global targeted therapeutics market during the forecast period.
Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=51390
Targeted Therapeutics Market: Prominent Regions
In terms of region, the global targeted therapeutics market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global targeted therapeutics market in 2020, followed by Europe. The U.S. dominated the targeted therapeutics market in North America in 2020, due to the presence of key players, adoption of targeted therapeutics monoclonal antibodies, and adequate reimbursement policies. This, in turn, is expected to boost the market in the region. The targeted therapeutics market in Asia Pacific is likely to expand at a high CAGR from 2021 to 2031. The growth of the market in the region can be attributed to the adoption of new targeted therapeutic drugs, increase in awareness about various oncological disorders, rise in healthcare expenditure, and high penetration of research activities across the region.
Strategic Acquisition and Collaborations by Key Players to Fuel Global Market
The global targeted therapeutics market is consolidated in terms of number of players. The market is dominated by key players with strong geographic presence. Key players operating in the global targeted therapeutics market include Amgen, Inc., F. Hoffmann-La Roche Ltd., AstraZeneca, Bristol-Myers Squibb Company, Bayer AG, Merck & Co., Inc., Novartis AG, and Pfizer, Inc. In March 2021, Amgen and Five Prime Therapeutics, a clinical-stage biotechnology company focused on developing immuno-oncology and targeted cancer therapies, announced an agreement under which Amgen will acquire Five Prime Therapeutics for US$ 38.00 per share in cash, representing an equity value of approximately US$ 1.9 Bn. This acquisition adds Five Prime's innovative pipeline to Amgen's leading oncology portfolio.
Pre Book Targeted Therapeutics Market Report at https://www.transparencymarketresearch.com/checkout.php?rep_id=51390<ype=S
In October 2020, Bristol-Myers Squibb and MyoKardia, Inc. announced a definitive merger agreement, under which Bristol-Myers Squibb will acquire MyoKardia for US$ 13.1 Bn, or US$ 225.00 per share in cash. The transaction was unanimously approved by the Boards of Directors of Bristol-Myers Squibb and MyoKardia and is anticipated to close during the fourth quarter of 2020. MyoKardia is a clinical-stage biopharmaceutical company discovering and developing targeted therapies for the treatment of serious cardiovascular diseases.
Browse More Trending Reports by Transparency Market Research:
Stem Cell Gun Devices Market: https://www.transparencymarketresearch.com/stem-cell-gun-devices-market.html
Revascularization Devices Market: https://www.transparencymarketresearch.com/revascularization-devices-market.html
Anesthesia Disposables Market: https://www.transparencymarketresearch.com/anesthesia-disposables-market.html
About Us
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.
ContactMr. Rohit BhiseyTransparency Market ResearchState Tower,90 State Street,Suite 700,Albany NY - 12207United StatesUSA - Canada Toll Free: 866-552-3453Email: sales@transparencymarketresearch.comWebsite: https://www.transparencymarketresearch.com/
Originally posted here:
Targeted Therapeutics Market: Increase in Incidence of Cancer to Drive Global Market - BioSpace
- Breast Cancer Is Most Common Cancer In India, 1.38 Million Cases Diagnosed Annually. Know Estimated Incidence By 2030 - ABP Live - November 26th, 2023
- What Is Amyloidosis? All About The Rare Disease That Pervez Musharraf Suffered From - ABP Live - February 8th, 2023
- Autophagic death of neural stem cells mediates chronic stress-induced ... - November 7th, 2022
- Programmed cell death - Wikipedia - November 7th, 2022
- Hematopoietic Stem Cells | Hematopoiesis | Properties & Functions - September 4th, 2022
- Canadian Blood Services Stem Cells for Life - September 4th, 2022
- Devastation over death of schoolgirl, 11, who hoped she was beating cancer - Leicestershire Live - September 4th, 2022
- From optimized stem cell transplants to CAR T cell therapy: Advancing options for cancer, HIV and more - City of Hope - September 4th, 2022
- Scientists unlock the key to immortality in jellyfish - Syfy - September 4th, 2022
- Forge Biologics Reports Positive Clinical Data on Brain Development and Motor Function from the RESKUE Novel Phase 1/2 Gene Therapy Trial in Patients... - September 4th, 2022
- Menin Inhibitors Have Potential to Become the Next Class of Targeted Therapy in AML - Targeted Oncology - September 4th, 2022
- Wanted murder suspect John Belfield believed to still be in the UK as two more arrested over death of Thomas Campbell - The Manc - September 4th, 2022
- Next-day manufacture of a novel anti-CD19 CAR-T therapy for B-cell acute lymphoblastic leukemia: first-in-human clinical study | Blood Cancer Journal... - July 8th, 2022
- Can minds persist when they are cut off from the world? - Livescience.com - July 8th, 2022
- Black Adolescent Young Adults With AML Have Worse Outcomes Vs White Population - Cancer Network - July 8th, 2022
- Akari Therapeutics Announces First Patient to Complete Course of Treatment in the Phase III Part A Clinical Trial of Investigational Nomacopan in... - July 8th, 2022
- How abortion ruling could affect IVF and embryonic research - The Almanac Online - July 8th, 2022
- This Morning viewers 'in tears' after boy meets donor who saved his life - Devon Live - July 8th, 2022
- Alpena detective: 'Good people out there' | News, Sports, Jobs - Alpena News - July 8th, 2022
- 'I miss my best friend': Five-year-old runs 10k to honour girl who died from rare brain tumour - Teesside Live - July 8th, 2022
- Humanigen Announces Peer-Reviewed Publication in Thorax Supporting Early Treatment of Hospitalized COVID-19 Patients with Lenzilumab Guided by... - July 8th, 2022
- Novartis AG, AstraZeneca Plc, and Pfizer Inc Among Leading Companies in the Thyroid Cancer Pipeline Products Market | Globaldata Plc - Yahoo Finance - July 8th, 2022
- A New Strategy Could Turn the Tide in Stem Cell GVHD - Medical Device and Diagnostics Industry - January 17th, 2022
- Vertex type 1 diabetes vs stem cell therapy - The Boar - January 17th, 2022
- Two-Year OS Doubles for Patients With Philadelphia-Positive Relapsed ALL After HSCT - AJMC.com Managed Markets Network - January 17th, 2022
- Nowakowski Considers CD19 Therapy in Transplant-Ineligible DLBCL - Targeted Oncology - January 17th, 2022
- Psaki demolishes Doocy with stats as he tries to claim covid now an illness of the vaccinated - newsconcerns - January 17th, 2022
- Doctors and Researchers Probe How COVID-19 Attacks the Heart - The Scientist - January 17th, 2022
- Who does donated blood that's direly needed help? - WTOP - January 17th, 2022
- Places Where Omicron is Most Contagious Eat This Not That - Eat This, Not That - January 17th, 2022
- UHN and U of T receive $24-million federal grant for transplant research - News@UofT - January 17th, 2022
- Glycyrrhizic acid ameliorates submandibular gland oxidative stress, autophagy and vascular dysfunction in rat model of type 1 diabetes | Scientific... - January 17th, 2022
- Stem cells in cancer therapy: opportunities and challenges - January 1st, 2022
- Life After Brain Death: Is the Body Still 'Alive'? | Live ... - January 1st, 2022
- Autologous Adult Stem Cells in the Treatment of Stroke | SCCAA - Dove Medical Press - January 1st, 2022
- Stem Cell Mimicking Nanoencapsulation for Targeting Arthrit | IJN - Dove Medical Press - January 1st, 2022
- Cellular Therapies Fill Unmet Needs in R/R Multiple Myeloma - Targeted Oncology - January 1st, 2022
- Upregulated expression of actin-like 6A is a risk factor | CMAR - Dove Medical Press - January 1st, 2022
- COVID-19 Takes a Toll on People with Blood Cancers and Disorders - Cancer Health Treatment News - January 1st, 2022
- Mental health disorders and heart diseases - Rising Kashmir - January 1st, 2022
- Research breakthrough could mean better treatment for patients with most deadly form of brain tumor - EurekAlert - October 26th, 2021
- European Commission Approves Merck's KEYTRUDA (pembrolizumab) Plus Chemotherapy as Treatment for Certain Patients With Locally Recurrent Unresectable... - October 26th, 2021
- European Commission Selects Humanigen's Lenzilumab as One of the 10 Most Promising Treatments for COVID-19 - Galveston County Daily News - October 26th, 2021
- Everything You Need To Know About COVID Booster Shots - Colorado Times Recorder - October 26th, 2021
- Stem cells and their role in lung transplant rejection - Michigan Medicine - October 5th, 2021
- Losing Your Hair? You Might Blame the Great Stem Cell Escape. - The New York Times - October 5th, 2021
- Will humans ever be immortal? - Livescience.com - October 5th, 2021
- Healthcare Researchers Are Putting HUMAN Immune Systems In Pigs To Study Illnesses-Here's The Tech Behind It - Tech Times - October 5th, 2021
- Why Bezos, Musk, Page and other billionaires want to live forever - New York Post - October 5th, 2021
- Faster healing of wounds can decrease pain and suffering and save lives - ABC 12 News - October 5th, 2021
- U.S. FDA Approves Kite's Tecartus as the First and Only Car T for Adults With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia - Business... - October 5th, 2021
- Skeletons' broken clavicles tell a centuries-old tale of humans and horses - Massive Science - October 5th, 2021
- Environmental Factor - August 2021: Extramural Papers of the Month - Environmental Factor Newsletter - August 4th, 2021
- Role of traumatic brain injury in the development of glioma | JIR - Dove Medical Press - August 4th, 2021
- Accumulation of Regulatory T Cells in Triple Negative Breast Cancer Ca | CMAR - Dove Medical Press - August 4th, 2021
- Novel CAR-T Cell Therapy Produces Early and Deep Responses in Certain Patients with Multiple Myeloma - Curetoday.com - June 7th, 2021
- Autophagy suppresses the formation of hepatocyte-derived cancer-initiating ductular progenitor cells in the liver - Science Advances - June 7th, 2021
- Cancer research: New advances and innovations - Medical News Today - June 7th, 2021
- Fulvestrant Alone Found to be Superior to Venetoclax/Fulvestrant Combo in ER+/HER2- Breast Cancer - Targeted Oncology - June 7th, 2021
- Merck's KEYTRUDA Given After Surgery Reduced the Risk of Disease Recurrence or Death by 32% Versus Placebo as Adjuvant Therapy in Patients With Renal... - June 7th, 2021
- Stem cell study illuminates the cause of an inherited heart disorder | Penn Today - Penn Today - February 14th, 2021
- The race to treat a rare, fatal syndrome may help others with common disorders like diabetes - Science Magazine - February 14th, 2021
- Jasper Therapeutics Announces Positive Data from Phase 1 Clinical Trial of JSP191 as Targeted Stem Cell Conditioning Agent in Patients with... - February 14th, 2021
- The Very First Signs of an Immune Response Have Been Filmed in a Developing Embryo - ScienceAlert - February 14th, 2021
- Arlo's Army needs stem cell donor as mum begs for help to save three-year-old's life - Glasgow Live - February 14th, 2021
- Astellas and Seagen Announce Phase 3 Trial Results Demonstrating Survival Advantage of PADCEV (enfortumab vedotin-ejfv) in Patients with Previously... - February 14th, 2021
- [Full text] Successful Use of Nivolumab in a Patient with Head and Neck Cancer Aft | OTT - Dove Medical Press - February 14th, 2021
- The drug treatments offering the best hope of a way out of the Covid crisis - Telegraph.co.uk - February 14th, 2021
- In the war against Covid, an arsenal of drugs is on the way - Telegraph.co.uk - February 14th, 2021
- Kat Wests husband, Jeff West, sentenced to 16 years in wifes death - AL.com - February 9th, 2021
- Harnessing the Potential of Cell and Gene Therapy - OncLive - February 9th, 2021
- I Survived Cancer, and Then I Needed to Remember How to Live - The Atlantic - February 9th, 2021
- [Full text] Higher Red Blood Cell Distribution Width is a Poor Prognostic Factor f | CMAR - Dove Medical Press - February 9th, 2021
- West Belfast woman to be remembered in special TV documentary - Belfast Live - January 29th, 2021
- UTV documentary tells of young Belfast woman's lasting legacy to promote stem cell donation - The Irish News - January 29th, 2021
- L-MIND Trial Results Show CD19 Antibody Is Reasonable in R/R DLBCL - Targeted Oncology - January 29th, 2021
- Vertex Announces FDA Clearance of Investigational New Drug (IND) Application for VX-880, a Novel Cell Therapy for the Treatment of Type 1 Diabetes... - January 29th, 2021
- If I Have Cancer, Dementia or MS, Should I Get the Covid Vaccine? - Kaiser Health News - January 29th, 2021
- Experimental taphonomy of organelles and the fossil record of early eukaryote evolution - Science Advances - January 29th, 2021
- Propanc Biopharma Appoints Belen Toledo to Evaluate Impact of Proenzyme Therapy on Tumor Microenvironment - Business Wire - January 29th, 2021